Micro-, Small-Cap Firms Dominate Market Rally

7. ALX Oncology Holdings Inc. (NASDAQ:ALXO)

ALX Oncology saw its share prices increase by 25.96 percent to finish at $1.31 apiece as investors cheered news of better earnings performance in the fourth quarter and full year of 2024.

In a statement, ALXO said net loss in the fourth quarter narrowed by 36 percent to $29.16 million from $45.47 million in the same period a year earlier, while net loss in the full year shrunk by 16 percent to $134.85 million from $160.8 million.

Loss from operations also declined by 36 percent to $30.6 million from $48 million in the same quarter, as well as by 16 percent to $142 million from $170 million in the full-year period.

Looking ahead, ALXO CEO Jason Lettmann said that its multiple ongoing clinical studies are set to position the company for near- and long-term success.